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Background: Medulloepithelioma (ME) is a rare embryonal tumor predominantly located in the eye or in the
central nervous system without an established treatment.
Case presentation: We report of a case of a localized peripheral ME treated with conventional and high dose
chemotherapy, surgery and local radiotherapy. At relapse, the tumor tissue revealed a different molecular signature
compared to the initial tumor mass. This molecular signature revealed a high expression of platelet derived growth
factor receptor (PDGFR). Sorafenib plus irinotecan and temozolomide was started with a 5 month progression free
survival.
Conclusion: Our experience suggests a possible role of sorafenib or different PDGFR inhibitors in ME. Targeting
treatment could represent an adjuvant and/or alternative therapy for ME and other rare tumors.
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Medulloepithelioma (ME) is a rare embryonal tumor with
a distinctive pathology characterized by papillary and
tubular patterns recalling the primitive epithelium of the
medullary plate and the embryonal neural tube [1].
ME is usually located in the eye or in central nervous
system (CNS); a peripheral location has been rarely re-
ported. Intraocular ME is often a well-circumscribed and
benign tumor, while CNS ME is an aggressive neoplasm
associated with a good prognosis only if completely re-
moved [2,3]. Considering the rarity of peripheral medul-
loephitelioma (PME), the optimal treatment has yet to be
established.
We report a case of PME with an interesting target pro-
tein expression suggesting a possible alternative thera-
peutic strategy for this rare tumor.Case presentation
A 3 year old female presented with a one-month his-
tory of abdominal pain and anorexia. The abdominal* Correspondence: mdebora.depasquale@opbg.net
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article, unless otherwise stated.ultrasonography showed a retroperitoneal mass (7 × 6 ×
6 cm) confirmed by CT scan with a right hydronephrosis
without evidence of metastatic spread (Figure 1A). An
open biopsy of the lesion was performed. The pathology
revealed a malignant neoplasm composed of tubules, pap-
illary structures, ribbons of primitive stratified columnar
cells, vesicular nuclei, and high nuclear-cytoplasmic ratio.
This histopathology is similar to the structure of the
primitive epithelium of the medullary plate and neural
tube. The absence of cilia and blepharoplasts ruled out the
hypothesis of a papillary ependymoma. The neoplastic
cells showed a diffuse positivity for CD56 and WT1 (cyto-
plasmic) and a variable positivity for NSE, Synaptophisin,
S100 protein and Cytokeratin MNF116, while they were
negative for CD99, alpha-fetoprotein, CD30, OCT3/4,
β-HCG. The diagnosis was neuroectodermal embryonal
tumor with patterns of ME (Table 1, Figure 2 and Figure 3).
The child started chemotherapy according to our local
protocol for Ewing Sarcoma Family Tumor [4]. After 2
ICE courses (Ifosfamide 2 gr/m2 for 3 days, Carboplatin
400 mg/m2 for 2 days and Etoposide 150 mg/m2 for
3 days) and 2 CAV (Cyclophosphamide 1.5 mg/m2 for
2 days, Vincristine 0.5 mg/m2 for 3 days and Doxorubicin
25 mg/m2 for 3 days), she achieved partial response, the
mass measuring 5 × 3.3 × 3.8 cm (Figure 1B). Grade 4ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 A: CT scans showing the tumor at diagnosis right hydronephrosis is also present; scans after 4 courses of CT, demonstrating partial
response to therapy; C: recurrence of the tumor after six months from stop therapy. CT at diagnosis (A), after chemotherapy (B) and at relapse (C).
De Pasquale et al. Journal of Translational Medicine 2014, 12:49 Page 2 of 6
http://www.translational-medicine.com/content/12/1/49bone marrow toxicity that required red blood cells and
platelets transfusion and hospitalization for neutopenic
fever, was recorded after all courses.
A complete resection of the lesion was performed. The
pathology showed extensive involutive post-chemotherapy
aspects. The residual viable tumor showed histologic as-
pects overlapping with these of the first biopsy, partly
characterized by more solid areas, with the same immuno-




WT1 ++ (cytoplasmatic) ++
NSE +- +-
Synaptophisin +- +-
S100 protein +- +-








ADAR 1 + +
ADAR 2 - -
LEGEND: EGFR, epidermal growth factor receptor; PDGFR, platelet-derived
growth factor receptor; ADAR, adenosine deaminases that act on RNA.The child, in complete remission, completed the treat-
ment with two CE courses (Cyclophosphamide 1.5 gr/m2
for 2 days and Etoposide 150 mg/m2 for 2 days) and a last
CAV course. As a consolidation treatment, she received a
high-dose chemotherapy based on Busulfan and Melphalan
with autologous peripheral blood stem cells rescue and, fi-
nally, radiotherapy to the primary tumor bed (19, 5 Gy).
During the entire chemotherapy treatment, only grade IV
bone marrow toxicity was recorded. During radiotherapy
the patient presented only grade I diarrhea.
Six months after treatment discontinuation, she pre-
sented with an abdominal relapse (Figure 1C). Surgery
was performed, achieving a second complete remission.
The pathology confirmed a ME with the same characteris-
tics of the primary tumor. At relapse, expression of tumor
target proteins was evaluated on tissue specimens ob-
tained both at diagnosis and at recurrence. Immunohisto-
chemistry showed the tumor cells always negative for
epidermal growth factor receptor (EGFR). By contrast,
there was some positive staining with platelet-derived
growth factor receptor (PDGFR) in the primary specimen,
with a few cellular clusters showing cytoplasmic positivity,
while at recurrence a clear diffuse cytoplasmatic positivity
for PDGFR reaching almost 100% of the cells was ob-
served. ADAR2 (adenosine deaminases that act on RNA)
was absent in both primary and recurrent tumors; ADAR1
was expressed in the nucleus and cytoplasm, both at diag-
nosis and at recurrence. Figure 5 shows the EGFR,
PDGFR, ADAR 1 and ADAR2 expression in tumor speci-
men at diagnosis and at recurrence. (See also Table 1).
According to the target protein expression, the patient
started sorafenib 200 mg once daily orally, plus temozolomide
Figure 2 Pathology of the tumor at diagnosis. Papillary and tubular patterns represent the distinctive appearance of medulloepithelioma;
HE 4 × (A). Positivity of the neoplastic cells for S100 protein 60× (B) and for PanCytokeratin 60× (C).
Figure 3 Pathology of the tumor at diagnosis. Areas of tumor at higher magnification show stratified columnar cells bordered by internal and
external limiting membrane HE 40× (A) and 60× (B). Positivity of the neoplastic cells for NSE 60× (C) and for CD56 60× (D).
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Figure 5 EGFR, PDGFR, ADAR 1 and ADAR2 expression in tumor spec
Figure 4 Pathology after chemotherapy. The post chemotherapy
tumor shows extensive involution area, calcifications HE4 × (A) and
a predominant solid pattern 4× (B).
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tecan 10 mg/m2/day orally for 14 consecutive days; the
course was repeated every 28 days.
Treatment was well tolerated, only generalized skin
rash associated with grade I dry skin not requiring treat-
ment discontinuation was recorded. A progression-free
survival was achieved for five months when peritoneal
carcinomatosis with an important neoplastic peritoneal
effusion appeared. The patient died for progressive dis-
ease a few weeks later.
Discussion
PME is a very rare neoplasm and only few reports
describe this entity (see Table 2 for more details) [5-9].
Similar to classical ME, surgery in PME, with or without
systemic chemotherapy and/or local radiotherapy, repre-
sents a therapeutic option. Complete surgery seems to
be associated with better outcome [5-9]. All reported
PME were located in the pelvic cavity (Table 2). Some
authors hypothesized that these tumors originated from
undifferentiated cells of the pre-sacral remnant [6]. Four
patients with ovarian ME had a good prognosis after
surgery either alone or associated with adjuvant chemo-
therapy and/or radiotherapy [5]. In a case of congenital
pelvic ME, prolonged disease-free survival was achieved
after partial surgical removal and chemotherapy [7]. In a
similar case, pelvic ME was resistant to chemotherapy
and the patient died of metastatic pulmonary progres-
sion [6].
Analyzing the reported cases, it seems that some PME
with favorable prognosis were sensitive to chemotherapy,imen at diagnosis and at recurrence.
Table 2 Review of literature for peripheral ME
Reference Sex Age Site Stage Metastasis Therapy Outcome
Kleinman et al. F 20 yr ovary I No Complete surgery, CT NED, 108 mo
Kleinman et al. F 32 yr ovary I No Complete surgery, CT NED, 36 mo
Kleinman et al. F 13 yr ovary III No Complete surgery DOD, 20 mo
Kleinman et al. F 23 yr ovary III No Complete surgery, CT, RT DOD, 2 mo
Figarella-Branger et al. F 17 yr pelvis IV Lung Surgery on primitive tumor, CT DOD, 8 mo
Bruggers et al. F Newborn pelvis III No Partial resection, CT NED, 50 mo
Donner et al. F 12 yr pelvis III No CT NED, 36 mo
Nakamura et al. M 6 mo pelvis (sciatic nerve) III No Complete surgery NED, 84 mo
Legend: F, female; M, male; yr, years; mo, months; CT, chemotherapy; RT, radiotherapy; NED, non evidence of disease; DOD, died of disease.
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ment was represented by radical surgery [5-9]. In our case,
we decided to treat the patient with an aggressive first-line
therapy. The patient achieved complete remission but she
relapsed only six months after the end of treatment. At re-
lapse we evaluated the expression of tumor target proteins
focusing on the protein expression profile often involved
in brain cancers with possible therapeutic implications,
such as PDGFR and EGFR. The PDGFR is a cell surface
receptor linked to a tyrosine kinase (TK) involved in sev-
eral processes, including autocrine cancer cells growth
and angiogenesis. Few PDGFR antagonists have been de-
veloped and introduced in clinical practice, such as sorafe-
nib or STI571/imatinib mesylate [10]. Similarly, EGFR is a
cell-surface receptor involved in DNA synthesis and cell
migration, adhesion and proliferation. Anticancer drugs
directed against EGFR include gefitinib, erlotinib and
cetuximab [11].
We also studied the ADARs (adenosine deaminases that
act on RNA) expression on tumor specimens. The ADARs
are enzymes responsible for Adenosine-to-Inosine conver-
sion on coding and non-coding RNA (such as microRNA)
that are emerging as important key proteins in cancers.
Recent evidences have connected ADARs (ADAR1 and
ADAR2) deregulation to several cancers [12].
Surprisingly, at recurrence, we observed PDGFR ex-
pression, not present at diagnosis, in almost all tumor
cells.
Sorafenib is a small molecular inhibitor of several TK
protein, such as vascular endothelial growth factor re-
ceptor, PDGFR and Raf kinases (more avidly C-Raf than
B-Raf). The drug has been approved by the U.S. Food
and Drug Administration for use in the treatment of
advanced renal cancer, unresectable hepatocellular car-
cinoma and locally recurrent or metastatic, progressive
differentiated thyroid carcinoma refractory to radioactive
iodine treatment [13-15]. Some authors showed that so-
rafenib blocks STAT3 (a signal transducer and activator of
transcription), as well as the expression of proteins regu-
lating the cell cycle and the apoptosis process, both in celllines and primary tumor cells of medulloblastoma. These
findings provide a rationale for treatment of pediatric me-
dulloblastoma with sorafenib [16]. ME is classified in the
group of the embryonal tumors together with medullo-
blastoma according to WHO classification.
At recurrence, we proposed, as compassionate treat-
ment, sorafenib plus temozolomide and irinotecan. After
obtaining IRB approval the three drug combination was
started. Treatment was well tolerated and only a mild
skin rash was observed.
Sorafenib was chosen according to the PDGFR expres-
sion on tumor specimen, while temozolomide and irino-
tecan had demonstrated activity in medulloblastoma
[17,18]. We anticipated an efficacy of this drug combin-
ation with a good tolerance and a good quality of life
considering the oral assumption.
The finding of poor expression of PDGFR at diagnosis
and its massive expression at relapse could suggest that
a cell clone with high expression of PDGFR was respon-
sible for the relapse. This leads us to hypothesize that
sorafenib, if it had been administered at diagnosis, could
have allowed to maintain a longer complete remission.
Conclusion
Our experience is only a single report, with obvious an-
ecdotal consideration. However this report may suggest
that in cases of ME the target protein expression in tumor
tissue should be evaluated aimed to identify possible
therapeutic targets. Moreover, a possible therapeutic role
of PDGFR inhibitors was never reported before.
A TK-inhibitor could be considered and employed also
during first line treatment. Indeed, only a multicentric
trial could asses the clinical benefit of TK inhibitors
combined with chemotherapy; clearly the tumour target
protein profile should be evaluated in different phases of
treatment as well as at diagnosis or after chemotherapy
or at relapse.
Furthermore, we would underline the importance of tar-
gets expression study in ME as in all rare pediatric tumors
with a poor prognosis in order to identify alternative
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monitoring of the protein expression profile in tumor
samples at reasonable time points during therapy ad-
ministration. This may help taking decisions in drug
selection including appropriate change or adjustment
of chemotherapy.
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